Study to Assess Long-Term Safety/Tolerability of Enobosarm (GTx 024) in Stress Urinary Incontinence
Status:
Terminated
Trial end date:
2018-09-21
Target enrollment:
Participant gender:
Summary
This open-label extension study, for subjects from the G201002 study, will provide additional
long-term safety and tolerability data for GTx-024. All subjects in this study will receive
GTx-024 3 mg orally, once daily.